Introduction
Despite the clinical improvement in therapy, heart failure (HF) remains a major cause of mortality and morbidity, affecting 5.7 million people in the USA with an estimated 5-year mortality as high as 50% in symptomatic patients. 1 As suggested by the American Heart
Association estimating risk of mortality in HF plays an important role in management and can be estimated with a number of risk scores. 2 For example, the Seattle-HF Model and more recently the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) score. These scores have been derived from large retrospective cohorts and are heavily weighted toward New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF). The MAGGIC score is a contemporary example comprising 13 discrete parameters. The model was developed through the use of 30 studies, which included patients with a wide range of age, LVEF, and NYHA functional class and was recently validated in a large Swedish HF registry. 5 Cardiopulmonary exercise (CPX) parameters including peak oxygen consumption (VO 2 ) and minute ventilation/carbon dioxide production (VE/VCO 2 ) slope are established markers of prognosis in HF [6] [7] [8] and are accepted metrics to guide the selection of patients for heart transplantation (HTx) or left ventricular assist device (LVAD) implantation. These CPX parameters have previously combined to develop the exercise physiology based HF score and added to established metrics of risk in the metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score. 9, 10 In parallel, rapid development in echocardiographic technology has led to an increased interest in deformation imaging and quantitative right heart metrics. Right atrial volume has been shown to be associated with long-term outcome in a single centre study of 192 patients but not tested in combination with validated scores. 11 Similarly, several papers have highlighted the importance of LV global longitudinal strain (LVGLS) and right ventricular function. 12, 13 Despite these findings, there has been limited investigation of the incremental value of a combination of deformation imaging, right heart metrics, and CPX parameters on these well-established scores, particularly in the sub-group of dilated cardiomyopathy (DCM).
In this prospective cohort study comprised of ambulatory patients diagnosed with DCM, we first sought to explore the relationship between echocardiographic and CPX parameters. Secondly, we aimed to determine whether a combination of these contemporary variables would have incremental prognostic value when compared with validated risk scores.
Methods

Study design
This study was a prospective cohort study from the Stanford Exercising Testing (SET) registry, approved by Stanford University's Institutional Review Board. Two hundred and eight consecutive patients with a new or prior diagnosis of DCM from 2 August 2005 to 16 January 2013 who underwent both a transthoracic echocardiogram and CPX on the same day were selected. Dilated cardiomyopathy was initially diagnosed by the presence of left ventricular end diastolic diameter > 55 mm, LVEF < _ 40% in the absence of coronary artery disease at the time of diagnosis. 2 All patients had previously undergone coronary angiography or nuclear imaging testing. Those with evidence of epicardial coronary artery disease were excluded (n = 44). Additional exclusion criteria included severe lung disease, end stage liver disease, or NYHA Class IV functional status at baseline.
The composite end point of the study was death, HTx, need for LVAD implantation or acute hospitalization for HF. Two physician cardiologists independently adjudicated outcomes through chart review for quality control. Data collection included demographics, haemoglobin level, sodium, and estimated Glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) Study equation. Medical therapy was documented at the time of echocardiography.
Echocardiography
All patients underwent baseline rest echocardiography using commercially available echo systems (iE33; Philips Medical Imaging, Eindhoven, The Netherlands). Digitized echocardiographic studies were analysed by the Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory on Xcelera workstations in accordance with published guidelines of the American Society of Echocardiography.
14 Two physicians independently analysed the acquired images and both were blinded to the results of CPX testing and clinical outcomes. Regarding specific echocardiographic variables, LVEF was calculated by manual contouring of triplane apical imaging. 15 Left ventricular global longitudinal strain was calculated from triplane apical imaging on manual tracings of the mid wall with the formula for Lagrangian strain % = 100 Â (L1 -L0)/L0), as previously described. 16 For quality control, the mitral annular reference points were used; in addition, the apical reference point was determined to be the furthest point of the left ventricle from the mitral annulus, and it was kept stable to avoid overestimating strain measures due to foreshortening. 17 Semi-automated GLS and systolic strain rate (SR) were assessed using software, Image Arena TM (TOMTEC Imaging System, Unterschleissheim, Germany) in the apical 4-chamber view for best quality control. 18 With tissue Doppler imaging, we used peak myocardial early diastolic velocity at the lateral mitral annulus and the assessment of trans mitral to tissue Doppler imaging early diastolic velocity ratio (E/E'). 19, 20 Right atrial volume index (RAVI) was calculated using
Simpson's method, in the 4-chamber view and indexed to body surface area. 11, 21 Right ventricular function was quantified using right ventricular fractional area change (RVFAC) free-wall RVGLS and tricuspid annular systolic excursion (TAPSE) as previously described. 22 
Cardiopulmonary exercise testing
Symptom-limited CPX ventilatory expired gas analysis was completed with an individualized RAMP treadmill protocol. 23 Ventilatory efficiency, VO 2 , VCO 2 , and other CPX variables were acquired breath by breath and averaged over 10 s intervals using CareFusion Oxygen Pro (San Diego, CA, USA) or CosMEd Quark (Rome, Italy) metabolic system. VE and VCO 2 responses throughout exercise were used to calculate the VE/VCO 2 slope via least squares linear regression (y = mx þ b,m = slope). 24 
Risk scores
Metrics for each of the considered risk scores are summarized in Table 1 .
The MAGGIC-HF risk score was calculated in each patient from 13 variables as previously described (see Supplementary data online, The CPX-HF score was calculated from VE/VCO 2 slope (> _34), abnormal heart rate recovery (HRR) (< _6 beats at 1 min), oxygen uptake efficiency slope (OUES) (>1.4), PetCO2 (<33 mmHg), and peak VO 2 (< _14 mL/kg/min) having scores of 7, 5, 3, 3, and 2, respectively. Patients were divided into Groups 1-3 (0-4, 5-15, [16] [17] [18] [19] [20] , with Group 1 representing patients with the lowest risk and Group 3 highest risk (see Supplementary data online, Table S2 ). 9 The MECKI score was calculated in all patients: it was computed as follows: 10.3464 25 We considered other HF risk scores; The Seattle-HF model requires 14 continuous and 10 categorical variables in its assessment of which not Right heart metrics and exercise performance in dilated cardiomyopathy
all the parameters were available at the time of testing. The Emphasis-HF score was derived from patients with only mild symptoms (NYHA Class II dyspnoea) and severely reduced ejection fraction (LVEF < 30%), which were not representative of the SET registry.
Statistical analysis
Baseline characteristics were expressed as means ± standard deviation for continuous normally distributed parameters and as median and interquartile range for non-normally continuous distributed variables. Categorical variables were presented as frequency and percentage. Comparison of groups was performed using Student's t-test. A correlation matrix ordered by hierarchical clustering and partial correlation maps were created to capture associations and discovery regularities within the set of echocardiographic and CPX variables. A log rank test was run to demonstrate significant differences in survival distribution for the cut offs in the established HF scores.
The association between acquired variables and outcome was analysed using Cox proportional hazards models. We avoided including variables that were collinear as determined by linear regression. To minimize over fitting, we considered variables that were found to be independent within the multivariate regression model in each of clinical, transthoracic echocardiography, and CPX subgroups. Variables represented within the HF risk score (for example NYHA, LVEF, or GFR by MDRD) were not reentered when determining incremental value of individual variables compared to the MAGGIC and MECKI scores. The incremental value of the factors independently associated with outcome in each of the described categories was assessed in steps, as usually done in clinical practice. The incremental prognostic benefit of each category was measured using 
Results
Baseline characteristics
Clinical, echocardiographic measures, CPX parameters, and risk scores are summarized in Table 2 . Nine patients (4.3%) had a history of atrial fibrillation though seven of these patients remained in sinus rhythm at the time of echocardiography. The vast majority of patients were on appropriate medical therapy for HF at baseline with betablocker therapy (86%) and either an angiotensin converting enzyme inhibitor or angiotensin 2 antagonist (87% Heart failure risk scores
In our cohort, the MAGGIC and MECKI scores were normally distributed, with a mean MAGGIC score of 16 ± 7, associated with a predicted 1-and 3-year mortality risk of 7% and 17.5%, respectively. As shown in Figure 1 , the MAGGIC, MECKI, and CPX-HF scores predicted outcome in our cohort with very good discrimination. None of the 208 patient had a CPX-HF score of greater than 15 (high risk group). One patient received five points for heart rate recovery < 6 beats at 1 min.
Echocardiography
Mean calculated LVEF was 33 ± 13% with detailed measures shown in Table 2 . Estimation of RVSP based on TR was possible in 148 (71.1%) of patients. There was a strong correlation between LVEF and each of LVGLS and LVSR suggesting collinearly (r = -0.89, P < 0.001; r = -0.86, P < 0.001). Good correlation was also observed between RVFAC and RVGLS (r = -0.72, P < 0.001).
CPX Analysis
The average peak respiratory exchange ratio was 1.1 ± 0.1 and mean peak VO 2 was 20.3 ± 10.5 mL/kg/min with 39% of patients being below the established threshold for advanced therapy in HF of 14 mL/kg/min. 46 patients (31%) had impaired ventilatory efficiency (VE/VCO 2 >34).
Correlates of exercise performance and CPX parameters
There was a weak to moderate correlation between resting measures of LV function and peak VO 2 (LVEF, r = 0.45, P < 0.001); LVGLS, (r = -0.46, P < 0.001). Of the echocardiographic variables, RAVI showed the strongest nominal correlation with VE/VCO 2 (r = 0.40, P < 0.001), although not statistically different compared to other echocardiographic measures. LVGLS and E/Ecorrected for age, sex, and body mass index (BMI) explained 53% of the variance in peak VO 2 . The addition of RV metrics increased the adjusted R 2 from 0.53 to 0.56 and replaced E/Ewith RVGLS in the model. Figure 2 highlights the correlation arranged by hierarchal clustering between variables, with visual clusters seen among measures of LV function, atrial size and VE/CO 2 and measures of exercise performance. Age correlated well with GFR, E, and peak HR. Partial correlation mapping offered the advantage to analyse the strength of relationships between two variables while controlling for the effect of the other remaining variables within the map, Figure 3 . There was a strong correlation between metrics of LV function, specifically LVEF, LVGLS, and LVSR. This relationship remained strong in the presence of right heart metrics and CPX parameters. Cardiopulmonary exercise testing parameters including peak VO 2 and VE/VCO 2 show an association though weak with LV metrics. RAVI was associated with VE/VCO 2 slope, though metrics of RV ventricular contraction had no statistically significant relationship. A multivariable Cox proportional hazard model was undertaken in each category of variables with independent variables shown in Table  4 . NYHA was the strongest clinical predictor of outcome and GFR was the only laboratory test associated with outcome in our cohort. Our echocardiographic model demonstrated RAVI and MAGGIC score were independently association with outcome ( Figure 4, upper) RAVI remained an independent correlate when this process was repeated with the MECKI score (without CPX variables as these are embedded within the MECKI score) (Figure 4, lower) . The independent association of RAVI to outcome remained for both scores when patients with a history of AF were excluded (see Supplementary data online, Table S3 ). When RAVI was removed there was a trend for RVFAC to be incremental to MAGGIC and MECKI scores (P = 0.12, P = 0.09, respectively).
Correlation analysis
Discussion
The main finding of our study is three-fold. We first demonstrate that RA size maintains prognostic value even after taking into account well-validated risk scores. Second, our study highlights the difference between functional class and fitness (or exercise performance) in patients with DCM, as NYHA class and peak VO 2 are complementary. Finally, our study critically analyses the value of advanced echocardiographic indices in view of the complex networks linking these cardiovascular parameters. Several studies have focused on developing risk scores in HF. Different risk scores may include a combination of clinical, anthropomorphic, basic or advanced imaging parameters [echocardiography, magnetic resonance imaging (MRI), nuclear medicine autonomic or perfusion defects], laboratory data, co-morbidities, and medication profiles. Few studies have been as robust as the MAGGIC score in deriving a large sample size with simple parameters. In comparison to the MECKI score, it does not integrate CPX parameters and in comparison of the Seattle-HF model, it does not take into account device therapy or medication dosing. Blood based biomarkers which are a focus of many studies have rarely been placed in the context of validated clinical models such as MAGGIC or MECKI scores.
The main contribution of our study is to integrate basic clinical models, to more advanced echocardiographic parameters and CPX data. Before analysing the incremental value of imaging and exercise performance parameters, we had to ensure our cohort was representative. The MAGGIC, CPX-HF, and the MECKI scores had a good discrimination of outcome demonstrating their robustness and the representability of our cohort. Among the echocardiographic and CPX parameters within the HF scores, several showed a normal distribution, consistent with previous validation studies. 5 ,25 HRR below 6 bpm was only observed in one patient in our cohort, explaining the absence of high-risk classification by the CPX-HF score. This may be partially explained by the high uptake of beta blocker therapy in the cohort. Several echocardiographic parameters emerged associated with outcome as seen in previous studies including atrial and ventricular chamber size, LVEF, tissue Doppler, and deformation imaging. 11, 12, 19, 26 The fact that LVEF in DCM is closely linked to LVGLS and LVSR decreases their potential complementarity in risk scores. We further define these relationships visually through the use of our correlation map arranged by hierarchal clustering. This extends the investigation by Kobayashi et al. 27 demonstrating that in a dilated ventricle there is a more collinear relationship between LVEF and strain, unlike HF preserved ejection fraction or hypertrophic conditions. In contrast, as shown in our partial correlation analysis, right heart parameters are more independent to left heart parameters, explaining recent findings that RV function is incremental to LVEF in risk predication models. 28, 29 Right atrial size is a parameter that has not been extensively studied in HF with reduced EF. Sallach et al. 11 showed that RAVI is independently associated with adverse clinical events and RV systolic dysfunction, even when corrected for age, BNP, RV systolic dysfunction, and LAVI in a moderate sized cohort of chronic HF patients. In our study, RA size also emerged independent to MAGGIC, MECKI scores and CPX parameters, further validating its importance. Although CPX parameters have been shown to be strongly related to outcome only a few have placed them in the context of advanced imaging parameters. Our findings support that exercise performance assessed by peak VO 2 is relatively independent of echocardiographic metrics. Our echocardiographic models only explained 53% of the variance in peak VO 2 . As observed in previous studies, multivariate analysis identified markers of right atrial remodelling, specifically RAVI to independently predict VE/VCO 2 slope and risk of an adverse event. 30 Our study also validates the previous finding that nonexercise test estimates of physical function, NYHA is our study, capture different information than peak VO 2, even when added to a comprehensive risk score such as the Seattle-HF model. 31, 32 Our study has several clinical implications. First it shows that simple parameters such as RA size could be sufficient to consider when exercise performance and clinical models are considered. Second, it is important to interpret variables of functional capacity such as NYHA and peak VO 2 separately. Third, the robustness of clinical models including those that incorporate CPX will make it hard for other biomarkers to emerge incremental and will require large cohorts. One question that arises is whether better predication will impact management. Apart from closer management in higher risk individuals, more studies will need to be performed. For example, whether NYHA class I but higher risk score could benefit from therapy such as spironolactone, however, this patient group will be difficult to capture.
Our data should be interpreted in the context of their limitation. Despite a cohort of over 200 patients with DCM representing a large study with simultaneous advanced echocardiographic and CPX data, it is however, still a smaller cohort compared to the larger trials. The representability of the cohort provides some reassurance as to the potential external validity of the findings. One limit to the modelling is that we did not have biomarkers such as BNP, hs-troponin, Galectin-3 or GDF-15 or MRI parameters, specifically myocardial fibrosis measured using delayed enhancement or T1 mapping sequence. These markers have recently emerged and it will be interesting, though challenging, to see their incremental value to risk models derived from other cohorts. Although RVSP has been shown to be a predictor of outcome in HF, our study among others, highlights the challenge in obtaining an accurate estimate of RVSP can limit its value in risk modelling. Finally, though we had a reasonable length of follow-up, we used a composite endpoint as opposed to mortality with a limited number of total events (n = 60) and so these findings should be viewed as preliminary. However, unlike previous studies our composite end point allowed validation of a cohort that included left ventricular assist device insertion, which is becoming an increasing part of advanced DCM management. 33 
Conclusion
Risk stratification in HF will remain an area of interest in order to allocate resources and treatment to those who are at the highest risk. In an era of emerging diagnostic techniques, CPX, specifically peak VO 2 will continue to play an important role. While great attention has been directed to newer echocardiographic techniques, simple established metrics such as RAVI should not be overlooked.
